Market Place
Sourcing Support
Alterity Therapeutics Featured at International MSA Congress
12 May 2025 //
GLOBENEWSWIRE
Alterity Therapeutics to Present at International MSA Congress
07 May 2025 //
GLOBENEWSWIRE
Alterity Therapeutics Granted FDA Fast Track for ATH434 for MSA
05 May 2025 //
GLOBENEWSWIRE
Alterity Therapeutics Presents ATH434-201 Trial Results at Europe
28 Apr 2025 //
GLOBENEWSWIRE
Alterity Therapeutics Presents New Data from ATH434 Phase 2 Trial
10 Apr 2025 //
GLOBENEWSWIRE
Alterity Therapeutics to Present Positive ATH434 Phase 2 Results
03 Apr 2025 //
GLOBENEWSWIRE
Alterity Completes ATH434-202 Ph 2 Trial in Multiple System Atrophy
27 Mar 2025 //
GLOBENEWSWIRE
Alterity Therapeutics Raises A$40.0 million in Placement
10 Feb 2025 //
GLOBENEWSWIRE
Alterity`s ATH434 Shows Positive Phase 2 Results In MSA
30 Jan 2025 //
GLOBENEWSWIRE
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
24 Jan 2025 //
GLOBENEWSWIRE
Alterity Issue Shareholder Letter Pipeline Advance & Key Milestone
09 Jan 2025 //
GLOBENEWSWIRE
Alterity Completes Patient Visit in ATH434-201 Ph 2 Trial for MSA
04 Dec 2024 //
GLOBENEWSWIRE
Alterity Appoints Abby Macnish Niven as Company Secretary
19 Nov 2024 //
GLOBENEWSWIRE
Alterity Presents at Symposium on Multiple System Atrophy
12 Nov 2024 //
GLOBENEWSWIRE
Alterity Therapeutics Publishes Novel Mechanism for ATH434
06 Nov 2024 //
GLOBENEWSWIRE
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
31 Oct 2024 //
GLOBENEWSWIRE
Alterity Therapeutics To Participate In Maxim Virtual Summit n 17 Oct
14 Oct 2024 //
GLOBENEWSWIRE
Alterity Presents ATH434 Neuroprotection Data at Neuroscience Meeting
11 Oct 2024 //
GLOBENEWSWIRE
Alterity Therapeutics Presents at Parkinson’s Disease Congress
02 Oct 2024 //
GLOBENEWSWIRE
Alterity Appoints Abby Macnish Niven As CFO
30 Sep 2024 //
GLOBENEWSWIRE
Alterity To Present At Parkinson`s And Movement Disorders Meet
23 Sep 2024 //
GLOBENEWSWIRE
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
31 Jul 2024 //
GLOBENEWSWIRE
Alterity Therapeutics to Present at MST Financial Webinar
24 Jul 2024 //
GLOBENEWSWIRE
Alterity Reports Positive Interim Data For ATH434 In MSA Trial
17 Jul 2024 //
GLOBENEWSWIRE
Alterity Therapeutics To Present At MST Access Life Sciences Webinar
12 Jun 2024 //
GLOBENEWSWIRE
Alterity Webcast On New bioMUSE Natural History Study Data
29 May 2024 //
GLOBENEWSWIRE
Alterity DMC Recommends Continuing Phase 2 Trial
08 May 2024 //
GLOBENEWSWIRE
Alterity Shows ATH434 Potential in Friedreich`s Ataxia
29 Apr 2024 //
GLOBENEWSWIRE
Alterity Parkinson`s Disease & Multiple System Atrophy Data Featured at the AAN
17 Apr 2024 //
GLOBENEWSWIRE
Alterity Therapeutics Presents New Data at World Orphan Drug Congress
10 Apr 2024 //
GLOBENEWSWIRE
Alterity Therapeutics Receives a A$3.9M R&D Tax Incentive Refund
26 Mar 2024 //
GLOBENEWSWIRE
Alterity to Present New Data at the American Academy of Neurology Meeting
20 Feb 2024 //
GLOBENEWSWIRE
Alterity Phase 2 Data Monitoring Committee Recommends Continuing Trial
06 Feb 2024 //
GLOBENEWSWIRE
Alterity Therapeutics to Participate in ShareCafe Hidden Gems Webinar This Week
29 Jan 2024 //
GLOBENEWSWIRE
Alterity Therapeutics Issues Shareholder Letter
22 Jan 2024 //
GLOBENEWSWIRE
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
20 Dec 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Reports Positive Efficacy Data for ATH434
04 Dec 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Announces Presentation of Novel Biomarker Data
27 Nov 2023 //
GLOBENEWSWIRE
Alterity Announces Presentation of Data Demonstrating Novel Mechanisms of ATH434
16 Nov 2023 //
GLOBENEWSWIRE
Appendix 4C “ Q1 FY24 Quarterly Cash Flow Report
30 Oct 2023 //
GLOBENEWSWIRE
Alterity Presents New Data on MSA, a Rare Parkinsonian Disorder
31 Aug 2023 //
GLOBENEWSWIRE
Alterity Granted Composition of Matter Patent for Neurodegenerative Disease
23 Aug 2023 //
GLOBENEWSWIRE
Alterity Receives a $4.74 million Research & Development Tax Incentive Refund
15 Aug 2023 //
GLOBENEWSWIRE
Appendix 4C Q4 FY23 Quarterly Cash Flow Report
31 Jul 2023 //
GLOBENEWSWIRE
Alterity PII Data Monitoring Committee Recommends Continuing Trial as Planned
26 Jul 2023 //
GLOBENEWSWIRE
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns
21 Jun 2023 //
GLOBENEWSWIRE
Alterity initiates new Phase II advanced MSA therapy trial
30 May 2023 //
CLINICAL TRIALS ARENA
Alterity Therapeutics CEO David Stamler to Present at SHARE Series Management
19 May 2023 //
GLOBENEWSWIRE
Appendix 4C “ Q3 FY23 Quarterly Cash Flow Report
10 May 2023 //
GLOBENEWSWIRE
Alterity doses first participant in Australia in Phase II trial of MSA
10 May 2023 //
CLINICAL TRIALS ARENA
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE
26 Apr 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Enrolls First Patient in ATH434 Phase 2 Trial
04 Apr 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Announces Granting of New Composition of Matter Patent
14 Mar 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Trial
08 Mar 2023 //
GLOBENEWSWIRE
Alterity Receives Regulatory Authorization to Proceed with ATH434 PII Trial
16 Feb 2023 //
GLOBENEWSWIRE
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
31 Jan 2023 //
PR NEWSWIRE
Alterity`s ATH434 Prevents Loss of Brain Cells in Parkinson`s Disease Model
30 Jan 2023 //
GLOBENEWSWIRE
Alterity Launches ATH434 PII Trial in Italy for the Treatment of MSA
25 Jan 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in United States
09 Jan 2023 //
PR NEWSWIRE
Alterity Announces Presentation of Data from bioMUSE Natural History Study
07 Nov 2022 //
PRNEWSWIRE
